Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
Publication/Presentation Date
2-1-2021
Abstract
Gastrointestinal cancers encompass a diverse class of tumors arising in the GI tract, including esophagus, stomach, pancreas and colorectum. Collectively, gastrointestinal cancers compose a high fraction of all cancer deaths, highlighting an unmet need for novel and effective therapies. In this context, the transmembrane receptor guanylyl cyclase C (GUCY2C) has emerged as an attractive target for the prevention, detection and treatment of many gastrointestinal tumors. GUCY2C is an intestinally-restricted protein implicated in tumorigenesis that is universally expressed by primary and metastatic colorectal tumors as well as ectopically expressed by esophageal, gastric and pancreatic cancers. This review summarizes the current state of GUCY2C-targeted modalities in the management of gastrointestinal malignancies, with special focus on colorectal cancer, the most incident gastrointestinal malignancy.
Volume
15
Issue
3
First Page
201
Last Page
217
ISSN
1752-0371
Published In/Presented At
Flickinger, J. C., Jr, Rappaport, J. A., Barton, J. R., Baybutt, T. R., Pattison, A. M., Snook, A. E., & Waldman, S. A. (2021). Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies. Biomarkers in medicine, 15(3), 201–217. https://doi.org/10.2217/bmm-2020-0359
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
33470843
Department(s)
Administration and Leadership
Document Type
Article